Dysregulated CD38 Expression on T Cells Was Associated with Rapidly Progressive Interstitial Lung Disease in Anti-melanoma Differentiation-associated Gene 5 Positive Dermatomyositis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Nov 26

PMID 39588376

Authors

Yixue Guo

Hongjiang Liu

Bo Chen

Keyi Zhang

Liye Meng

Lin Yan

Qian Niu

Junlong Zhang

Geng Yin

Yi Li

Affiliations

Soon will be listed here.

Abstract

Background: Anti-melanoma differentiation-associated gene 5 positive dermatomyositis (MDA5+ DM) is a life-threatening disease due to rapidly progressive interstitial lung disease (RP-ILD). We aimed to investigate the expression profile of T cell subsets in MDA5+ DM patients, seeking for possible disease-causing T cell subsets and potential biomarkers to distinguish ILD, especially RP-ILD patients.

Methods: Peripheral blood T cell subpopulations were immunophenotyped in 24 MDA5+ DM patients and 21 healthy controls (HCs) by flow cytometry. The proportion of T cell subsets and clinical characteristics were analyzed. The quantitative determination of cytokines in the plasma was measured by using a microsphere-based immunofluorescence assaying kit.

Results: The proportion of naïve and CD38+ T cells were much higher, whereas the proportion of central memory T cells were lower in MDA5+ DM patients than in HCs. Notably, the proportion of CD38+CD4+ T cells and CD38+CD8+ T cells on T cells in in RP-ILD group were significantly elevated compared to C-ILD, non-ILD group and HCs. Moreover, serum IFN-α levels were significantly increased in MDA5+ DM patients with RP-ILD. Further, the frequencies of CD38+CD4+ T cells and CD38+CD8+ T cells were positively correlated with IFN-α levels. Finally, ROC analysis indicated that CD38+CD4+ T cells and CD38+CD8+ T cells could be potential biomarkers for predicting ILD/RP-ILD in MDA5+ DM patients.

Conclusion: Dysregulated CD38 expression on T cell subsets was associated with lung involvement, especially RP-ILD in MDA5+ DM patients. CD38+ T cell subsets could be used as potential biomarkers for predicting ILD/RP-ILD in MDA5+ DM patients.

References

Motegi S, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M . Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol. 2019; 29(5):511-517. DOI: 10.1684/ejd.2019.3634. View

Holzer M, Nies J, Oqueka T, Huber T, Kotter I, Krusche M . Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis. Chest. 2023; 163(1):e1-e5. DOI: 10.1016/j.chest.2022.08.2209. View

Wang C, Yang H, Li T, Wen Y, Yang H, Tang W . Analysis of characteristics related to interstitial lung disease or pulmonary hypertension in patients with dermatomyositis. Clin Respir J. 2023; 17(12):1328-1340. PMC: 10730463. DOI: 10.1111/crj.13720. View

Zhang L, Xia Q, Li W, Peng Q, Yang H, Lu X . The RIG-I pathway is involved in peripheral T cell lymphopenia in patients with dermatomyositis. Arthritis Res Ther. 2019; 21(1):131. PMC: 6542107. DOI: 10.1186/s13075-019-1905-z. View

Qian J, Xu H . COVID-19 Disease and Dermatomyositis: A Mini-Review. Front Immunol. 2022; 12:747116. PMC: 8792859. DOI: 10.3389/fimmu.2021.747116. View

Ye Y, Chen Z, Jiang S, Jia F, Li T, Lu X . Single-cell profiling reveals distinct adaptive immune hallmarks in MDA5+ dermatomyositis with therapeutic implications. Nat Commun. 2022; 13(1):6458. PMC: 9617246. DOI: 10.1038/s41467-022-34145-4. View

Long S, Thorpe J, DeBerg H, Gersuk V, Eddy J, Harris K . Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Sci Immunol. 2017; 1(5). PMC: 5486405. DOI: 10.1126/sciimmunol.aai7793. View

Jin Q, Fu L, Yang H, Chen X, Lin S, Huang Z . Peripheral lymphocyte count defines the clinical phenotypes and prognosis in patients with anti-MDA5-positive dermatomyositis. J Intern Med. 2023; 293(4):494-507. DOI: 10.1111/joim.13607. View

Savarino A, Bottarel F, Calosso L, Feito M, Bensi T, Bragardo M . Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle. FASEB J. 1999; 13(15):2265-76. DOI: 10.1096/fasebj.13.15.2265. View

10.

Lu X, Peng Q, Wang G . Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. Nat Rev Rheumatol. 2023; 20(1):48-62. DOI: 10.1038/s41584-023-01054-9. View

11.

Walsh R, Kong S, Yao Y, Jallal B, Kiener P, Pinkus J . Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007; 56(11):3784-92. PMC: 2443782. DOI: 10.1002/art.22928. View

12.

Ferrero E, Malavasi F . Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+-converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and.... J Immunol. 1997; 159(8):3858-65. View

13.

Moghadam-Kia S, Oddis C, Sato S, Kuwana M, Aggarwal R . Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care Res (Hoboken). 2015; 68(5):689-94. PMC: 4864500. DOI: 10.1002/acr.22728. View

14.

Hensgens M, Delemarre E, Drylewicz J, Voortman M, Krol R, Dalm V . Clinical features and immune-related protein patterns of anti-MDA5 positive clinically amyopathic dermatomyositis Dutch patients. Rheumatology (Oxford). 2022; 61(10):4087-4096. DOI: 10.1093/rheumatology/keac030. View

15.

Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S . The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford). 2018; 58(5):786-791. DOI: 10.1093/rheumatology/key386. View

16.

Ali S, R N, Sen P, Day J, Joshi M, Nune A . Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies: results from the COVAD study. Rheumatology (Oxford). 2023; 62(9):e263-e268. DOI: 10.1093/rheumatology/kead149. View

17.

Chen M, Quan C, Diao L, Xue F, Xue K, Wang B . Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol. 2018; 179(6):1334-1341. DOI: 10.1111/bjd.17079. View

18.

Takada T, Ohashi K, Hayashi M, Asakawa K, Sakagami T, Kikuchi T . Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. Respir Med. 2018; 141:7-13. DOI: 10.1016/j.rmed.2018.06.012. View

19.

Gelman L, Deterre P, Gouy H, Boumsell L, Debre P, Bismuth G . The lymphocyte surface antigen CD38 acts as a nicotinamide adenine dinucleotide glycohydrolase in human T lymphocytes. Eur J Immunol. 1993; 23(12):3361-4. DOI: 10.1002/eji.1830231245. View

20.

Kar A, Mehrotra S, Chatterjee S . CD38: T Cell Immuno-Metabolic Modulator. Cells. 2020; 9(7). PMC: 7408359. DOI: 10.3390/cells9071716. View